According to our (Global Info Research) latest study, the global Live Attenuated Veterinary Vaccines market size was valued at US$ 453 million in 2025 and is forecast to a readjusted size of US$ 773 million by 2032 with a CAGR of 8.2% during review period.
In 2025, global Live Attenuated Veterinary Vaccine approximately 16,943 k doses, with an average global market price of around US$ 26 per dose. Gross margin is about 47%. The cost is 14 usd. The Production is about 25,000 k doses. Live attenuated veterinary vaccines are biological products used to prevent infectious diseases in animals. They are made from pathogens that have been artificially weakened so that their disease-causing ability is greatly reduced while their capacity to stimulate an immune response remains. These vaccines usually provide strong and long-lasting immune protection and are widely used in poultry, swine, cattle, sheep, companion animals, and other animal disease prevention programs. Compared with inactivated vaccines, live attenuated vaccines often require lower doses and can induce faster immune responses, but they also require stricter control over production, storage, transportation, safety, and stability.
Live attenuated veterinary vaccines will develop toward greater safety, stability, precision, and efficiency. As large-scale farming and animal disease prevention requirements continue to rise, manufacturers will focus more on attenuation stability, duration of immunity, cross-protection, and cold-chain stability to reduce risks such as reversion to virulence, shedding, and environmental transmission. At the same time, genetic attenuation, reverse genetics, vector-based vaccines, and multivalent combination vaccines will drive product innovation, enabling broader protection against multiple pathogens or serotypes. In application, mass vaccination methods such as spray, drinking water, and intranasal delivery will become more widely used and integrated with digital disease monitoring and precise vaccination programs to improve efficiency across poultry, swine, cattle, sheep, and companion animal markets.
This report is a detailed and comprehensive analysis for global Live Attenuated Veterinary Vaccines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Live Attenuated Veterinary Vaccines market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Live Attenuated Veterinary Vaccines market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Live Attenuated Veterinary Vaccines market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Live Attenuated Veterinary Vaccines market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live Attenuated Veterinary Vaccines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live Attenuated Veterinary Vaccines market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Ceva Santé Animale, Boehringer Ingelheim Animal Health, MSD Animal Health, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, IDT Biologika, Vaxxinova, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Live Attenuated Veterinary Vaccines market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Poultry
Ruminants
Feline
Canine
Market segment by Pathogen
Viral Live Attenuated Vaccines
Bacterial Live Attenuated Vaccines
Parasitic Live Attenuated Vaccines
Market segment by Vaccine Combination
Monovalent Live Attenuated Vaccines
Multivalent Live Attenuated Vaccines
Combination Live Attenuated Vaccines
Market segment by Application
Veterinary Hospital
Laboratory
CROs
Others
Major players covered
Zoetis
Ceva Santé Animale
Boehringer Ingelheim Animal Health
MSD Animal Health
Virbac
HIPRA
Vetoquinol
Phibro Animal Health
IDT Biologika
Vaxxinova
KBNP Inc.
China Pharmaceutical Group Animal Health Co., Ltd.
Jinyu Bio-technology Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Live Attenuated Veterinary Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Live Attenuated Veterinary Vaccines, with price, sales quantity, revenue, and global market share of Live Attenuated Veterinary Vaccines from 2021 to 2026.
Chapter 3, the Live Attenuated Veterinary Vaccines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live Attenuated Veterinary Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Live Attenuated Veterinary Vaccines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Live Attenuated Veterinary Vaccines.
Chapter 14 and 15, to describe Live Attenuated Veterinary Vaccines sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Live Attenuated Veterinary Vaccines. Industry analysis & Market Report on Live Attenuated Veterinary Vaccines is a syndicated market report, published as Global Live Attenuated Veterinary Vaccines Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Live Attenuated Veterinary Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.